| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10103537 | Journal of the American College of Surgeons | 2005 | 8 Pages |
Abstract
Neoadjuvant chemotherapy can be effectively applied to patients with stage II disease, and breast conservation becomes feasible in the majority of patients. When compared with historic controls, the current study suggests a statistically significant overall survival advantage (p < 0.007) at 5 years.
Related Topics
Health Sciences
Medicine and Dentistry
Surgery
Authors
Gordon F. MD, Andrew J. MD, Elizabeth A. MD, Joshua P. MD, Paul G. MD,